An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.
about
Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasisGene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathwayNon-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary resultsSuppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapyPAGE: parametric analysis of gene set enrichmentA HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomasSystematic survey reveals general applicability of "guilt-by-association" within gene coexpression networksThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersA mouse stromal response to tumor invasion predicts prostate and breast cancer patient survivalKRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapyIntegrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setA high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafishIntegrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and oldEvidence-based annotation of the malaria parasite's genome using comparative expression profilingIdentification of gene expression signature modulated by nicotinamide in a mouse bladder cancer modelXmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinomaMolecular credentialing of rodent bladder carcinogenesis models.Imaging primary lung cancers in mice to study radiation biology.GSVA: gene set variation analysis for microarray and RNA-seq data.Image-guided radiotherapy platform using single nodule conditional lung cancer mouse modelsUsing large-scale molecular data sets to improve breast cancer treatment.A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to ChemotherapyApplication of a priori established gene sets to discover biologically important differential expression in microarray data.Modeling cancer progression via pathway dependenciesMultiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumorsA mouse to human search for plasma proteome changes associated with pancreatic tumor development.SLEPR: a sample-level enrichment-based pathway ranking method -- seeking biological themes through pathway-level consistencyRegulatory subunits of PKA define an axis of cellular proliferation/differentiation in ovarian cancer cellsCross-species comparison of biological themes and underlying genes on a global gene expression scale in a mouse model of colorectal liver metastasis and in clinical specimens.Statistical issues and analyses of in vivo and in vitro genomic data in order to identify clinically relevant profiles.Molecular characterization of lung dysplasia induced by c-Raf-1.Integration of heterogeneous expression data sets extends the role of the retinol pathway in diabetes and insulin resistance.Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.GSMA: Gene Set Matrix Analysis, An Automated Method for Rapid Hypothesis Testing of Gene Expression Data.Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiencyGene set enrichment meta-learning analysis: next- generation sequencing versus microarraysBabelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling.A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
P2860
Q24310324-32286B05-CB31-45BA-B1E2-5F3FA9A6ADB8Q24310644-F087F238-4B51-4FFB-ABC8-02D19DD97F4CQ24536351-183450B6-D8AF-4693-AD48-A69CF89ABDF3Q24621007-2DDCB6EC-6A66-4647-BF15-7613D7CE92E5Q24630546-55401D97-138A-4E62-99F2-4BE3DF30C1EFQ24631616-AA49055E-AE64-4E61-8A59-117AA440E5BFQ24810449-D4A652DF-8EF5-4FBB-8B23-101DCD32DAF7Q24811594-AAED7969-8258-4FC3-B98F-80D7A6E3E5CEQ24817215-6E77CA6C-33CB-4BE2-8396-C949FBDC5F4BQ26747403-92B61C0E-B8BC-48DD-9819-D83FB7D62F23Q27303204-FC81FCE6-2DF6-4018-8B98-CF1D4222F133Q28069764-6B31AEFC-3166-4D18-B5C7-7CE1BC26BF3EQ28389579-873BB53C-24DE-43C7-8A39-5CFE5B2B2CF2Q28393439-4A459187-BADD-4A63-966A-9966B896E689Q28396741-83EC007F-2303-4812-B9D1-D88F3E081F4BQ28472095-55A6A7F5-9ECE-4BF4-94B9-CD3C51567F91Q28477425-7FAB9EAB-43C0-452D-9C61-C3B4386DB8A6Q28540910-8DEBD7CB-62DF-4424-AF45-394E8A2E5354Q30441327-ED9653D3-83DF-4D59-A998-81E5FFFE1EE1Q30493924-D58C246B-B030-4726-A60F-AA0FE6FB258BQ30586230-044F6AD3-829E-420A-9FF2-133085504A17Q30610005-7391E182-D2B8-4FAC-8D31-168573770508Q30656126-1386CA2D-B130-4295-8C9F-40CED98CBA71Q30742035-AF23FF1E-C86D-4E7B-831C-539D02D23FD3Q31011778-57D79896-22BB-45EE-8866-BAE06F1CDBC9Q33320177-A36CBDF3-CB8E-4323-B3C1-3B28DA446595Q33324395-E33FE221-BCEF-468F-8482-2C61E25D94CAQ33343004-947BAB19-BC8F-4BD6-AD6B-4F522915709CQ33372132-15842255-AFA0-4D6E-BD3F-03B074226027Q33372446-61EC87D3-FCE6-4FA2-9609-B661E272E568Q33372604-A6DB3F76-A1B7-4235-9B1C-FD2D51A61649Q33392732-111034EC-4241-4E3E-BEBD-BAF2EFEE6820Q33468458-1953B5B6-FB44-4E72-8129-E8BBE6E9F5F4Q33507213-4948A1B4-4C72-4703-9CF1-7FAC8B3DA2DBQ33511579-8FD0E60A-917C-4253-B9D2-C05B404E4BBBQ33523288-C6F68B22-EFC3-48C4-B8D8-2CDEF6A5EC61Q33544002-97BD81C8-15E8-482F-B7F5-08D1F75BEAFCQ33551033-D8054C82-DAC8-468E-BEB1-0DE71ED1A432Q33579781-5C862BF1-108E-4492-A2F2-733DEEFF4907Q33621880-B348B5F4-7802-4870-9BC1-261D497F3010
P2860
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
An oncogenic KRAS2 expression ...... cies gene-expression analysis.
@en
An oncogenic KRAS2 expression ...... cies gene-expression analysis.
@nl
type
label
An oncogenic KRAS2 expression ...... cies gene-expression analysis.
@en
An oncogenic KRAS2 expression ...... cies gene-expression analysis.
@nl
prefLabel
An oncogenic KRAS2 expression ...... cies gene-expression analysis.
@en
An oncogenic KRAS2 expression ...... cies gene-expression analysis.
@nl
P2093
P2860
P50
P356
P1433
P1476
An oncogenic KRAS2 expression ...... cies gene-expression analysis.
@en
P2093
Alejandro Sweet-Cordero
Aravind Subramanian
Christine Ladd-Acosta
Jeffrey J Roix
Todd R Golub
Tyler Jacks
P2860
P2888
P356
10.1038/NG1490
P407
P577
2004-12-19T00:00:00Z